| SZYMAŃSKA K, K., L. E. MOORE, N. ROTHMAN, W.H. CHOW, F. WALDMAN, E. JAEGER, T. WATERBOER, Lenka FORETOVÁ, M. NAVRATILOVA, V. JANOUT, H. KOLLAROVA, D. ZARIDZE, V. MATVEEV, D. MATES, N. SZESZENIA-DABROWSKA, I. HOLCATOVA, V. BENCKO, F. LE CALVEZ-KELM, S. VILLAR, M. PAWLITA, P. BOFFETTA, P. HAINAUT a P. BRENNAN. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer letters. 2010, roč. 293, č. 1, s. 92-98. ISSN 0304-3835. Dostupné z: https://dx.doi.org/10.1016/j.canlet.2009.11.024. |
Další formáty:
BibTeX
LaTeX
RIS
@article{923445,
author = {Szymańska K, K. and Moore, L. E. and Rothman, N. and Chow, W.H. and Waldman, F. and Jaeger, E. and Waterboer, T. and Foretová, Lenka and Navratilova, M. and Janout, V. and Kollarova, H. and Zaridze, D. and Matveev, V. and Mates, D. and SzeszeniaandDabrowska, N. and Holcatova, I. and Bencko, V. and Le CalvezandKelm, F. and Villar, S. and Pawlita, M. and Boffetta, P. and Hainaut, P. and Brennan, P.},
article_number = {1},
doi = {http://dx.doi.org/10.1016/j.canlet.2009.11.024},
keywords = {TP53 mutations; VHL; EGFR; Cancer; Renal carcinoma},
language = {eng},
issn = {0304-3835},
journal = {Cancer letters},
title = {TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.},
volume = {293},
year = {2010}
}
TY - JOUR
ID - 923445
AU - Szymańska K, K. - Moore, L. E. - Rothman, N. - Chow, W.H. - Waldman, F. - Jaeger, E. - Waterboer, T. - Foretová, Lenka - Navratilova, M. - Janout, V. - Kollarova, H. - Zaridze, D. - Matveev, V. - Mates, D. - Szeszenia-Dabrowska, N. - Holcatova, I. - Bencko, V. - Le Calvez-Kelm, F. - Villar, S. - Pawlita, M. - Boffetta, P. - Hainaut, P. - Brennan, P.
PY - 2010
TI - TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.
JF - Cancer letters
VL - 293
IS - 1
SP - 92-98
EP - 92-98
SN - 03043835
KW - TP53 mutations
KW - VHL
KW - EGFR
KW - Cancer
KW - Renal carcinoma
N2 - Renal-cell carcinomas (RCC) are frequent in central and eastern Europe and the reasons remain unclear. Molecular mechanisms, except for VHL, have not been much investigated. We analysed 361 RCCs (334 clear-cell carcinomas) from a multi-centre case-control study for mutations in TP53 (exons 5-9 in the whole series and exons 4 and 10 in a pilot subset of 60 tumours) and a pilot 50 tumours for mutations in EGFR (exons 18-21) or KRAS (codon 12) in relation to VHL status. TP53 mutations were detected in 4% of clear-cell cases, independently of VHL mutations. In non-clear-cell carcinomas, they were detected in 11% of VHL-wild-type tumours and in 0% of tumours with VHL functional mutations. No mutations were found in EGFR or KRAS. We conclude that mutations in TP53, KRAS, or EGFR are not major contributors to the RCC development even in the absence of VHL inactivation. The prevalence of TP53 mutations in relation to VHL status may differ between clear-cell and other renal carcinomas.
ER -
SZYMA$\backslash$'NSKA K, K., L. E. MOORE, N. ROTHMAN, W.H. CHOW, F. WALDMAN, E. JAEGER, T. WATERBOER, Lenka FORETOVÁ, M. NAVRATILOVA, V. JANOUT, H. KOLLAROVA, D. ZARIDZE, V. MATVEEV, D. MATES, N. SZESZENIA-DABROWSKA, I. HOLCATOVA, V. BENCKO, F. LE CALVEZ-KELM, S. VILLAR, M. PAWLITA, P. BOFFETTA, P. HAINAUT a P. BRENNAN. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. \textit{Cancer letters}. 2010, roč.~293, č.~1, s.~92-98. ISSN~0304-3835. Dostupné z: https://dx.doi.org/10.1016/j.canlet.2009.11.024.
|
